hypertension

Target-HTN trial: Lorundrostat in Hypertension

The TARGET-HTN trial, published in JAMA in September 2023, investigated the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in treating patients with uncontrolled hypertension. This randomized, placebo-controlled, dose-ranging trial included 200 patients who were adults with uncontrolled hypertension … Read More

RADIANCE-HTN TRIO Trial: Renal Denervation in HTN

The RADIANCE-HTN TRIO trial, detailed in The Lancet in 2021, is another pivotal study in the domain of hypertension treatment, focusing on a challenging group of patients: those resistant to a standard triple combination pill. This trial delves into the … Read More

RADIANCE-HTN SOLO Trial: Renal Denervation in HTN

The RADIANCE-HTN SOLO trial, published in The Lancet in May 2018, marks a significant stride in hypertension treatment research. This trial focused on the safety and efficacy of a novel endovascular ultrasound renal denervation procedure compared to a sham procedure … Read More

DCP Trial Summary: HCTZ vs Chlorthalidone

2022 DCP TRIAL Chlorthalidone compared with hydrochlorothiazide for the preven- tion of cardiovascular events in patients with hypertension: The Diuretic Comparison Project (DCP) Open-label, pragmatic, randomized controlled trial Objective: To compare the differences between hydrochlorothiazide (HCTZ) compared with chlorthalidone in … Read More

TIME Trial Summary: Morning vs. Evening dose of Antihypertensives

2022 TIME TRIAL Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK prospective, open-label, blinded-endpoint, randomized controlled trial IM Objective: To compare the major cardiovascular outcomes of evening dosing of antihypertensive medication … Read More

SUPPORT Trial Summary: Olmesartan in CHF

2015 SUPPORT TRIAL M Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure (CHF) prospective, open-label, randomized controlled trial Objective: to examine whether an additive treatment with an ARB, olmesartan, reduces the mortality and morbidity … Read More

ALLHAT-LLT Trial Summary: Pravastatin in Moderate HLD

2002 ALLHAT-LLT Pravastatin vs Usual Care in Moderately Hypercholesterolemic, Hypertensive Patients Multicenter, randomized, nonblinded trial M Objective: To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholes- terolemic, hypertensive participants with at least 1 additional … Read More

PADN-CFDA Trial Summary: PA Denervation for PAH

2022 PADN-CFDA TRIAL Pulmonary artery denervation for pulmonary arterial hypertension (PAH) multicenter, sham-controlled single-blind, randomized controlled trial Objective: To evaluate the treatment effects of pulmonary artery denervation (PADN) among patients with Group I PAH who were not on PAH-specific drugs … Read More

ACCOMPLISH Trial: Benazepril + Amlodipine or HCTZ for Hypertension

2008 ACCOMPLISH TRIAL Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients Multi-centered, double-blind, randomized, controlled trial Objective: To evaluate the effect of amlodipine vs. hydrochlorothiazide in patients with hypertension and at high risk for cardiovascular disease. E 11,506 … Read More

ACCORD BP Trial Summary: Intensive BP Control in Type 2 Diabetes

2010 ACCORD BP TRIAL Effects of intensive blood-pressure control in type 2 diabetes mellitus Multicenter, randomized, controlled, open-label trial Objective: In patients with T2DM at high risk for CV events, does intensive BP control (SBP <120 mmHg) reduce rates of … Read More